Efficacy of Smartphone App for Smoking Cessation in China
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04421170 |
Recruitment Status :
Recruiting
First Posted : June 9, 2020
Last Update Posted : January 24, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Cigarette Smoking Smartphone App-based Smoking Cessation | Behavioral: smartphone app for smoking cessation | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 1200 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Efficacy of Cognitive Behavioral Therapy-based Smartphone App for Smoking Cessation in China: a Study Protocol of a Randomized Controlled Trial |
Actual Study Start Date : | February 23, 2021 |
Estimated Primary Completion Date : | August 30, 2022 |
Estimated Study Completion Date : | February 28, 2023 |

Arm | Intervention/treatment |
---|---|
Experimental: Intervention Group
Participants from the intervention group will receive CBT based smoking cessation. It provides both mandatory information of evidence-based and guideline-based smoking cessation interventions, and optional information about quitting benefits, tips for quitting et al. The app will be available for the participants in the intervention group until 26-week post-quit date follow-up. After this period, the app will automatically stop the data collection, but they can continue to use it if they want. As the participants progressed through the study, smoking cessation related information will be gradually reduced until 12 weeks after quit date, and follow-up messages will be sent at 16, 20 and 26 weeks after quit date. Participants from intervention group can also seek for help at any time by text or WeChat, or make a phone call.
|
Behavioral: smartphone app for smoking cessation
Paticipants will receive 12-week app-based smoking cessation intervention with follow-up to 26 weeks. |
No Intervention: Control group
Participants from the control group will only receive information of thanking them for being in the study and reminding them of the time until their free month at the end of follow up. In order to measure the outcomes between two groups, continuous smoking abstinence, point prevalence of abstinence, how many cigarettes per day during the last week if they are still smoking will be checked at week 1, 2, 3, 4, 8, 12, 16, 20 and 26 points after quit date by ePRO software. Biochemically verified continuously abstinence will also be checked if they have reported continuous smoking abstinence at week 26 points after quit date.
|
- Biologically verified continuously smoking abstinence at week 26 [ Time Frame: 26 weeks ]Participants in this study will be considered to be biologically verified continuously smoking abstinence if they report smoking no more than 5 cigarettes since the quit date and have an expired carbon monoxide concentration of less than 10 ppm (for local participants who will be able to go to the PI affiliated hospital) or a urine cotinine cutoff point of 200 ng/ml (cotinine urine dipsticks will be mailed to each participant's address, and test will be confirmed by video call and by family members) at week 26 (6 months) after quit date. This abstinence has been applied by the Society for Research on Nicotine and Tobacco (SRNT) (Hughes, Keely et al. 2003) and the 'Russell Standard' (West, Hajek et al. 2005).
- 7-day point prevalence smoking abstinence [ Time Frame: 26 weeks ]7-day Point prevalence of smoking abstinence: not even a puff of smoke, for the last seven consecutive days, at 1, 2, 3, 4, 8, 12, 16, 20 and 26 weeks.
- Self-reported continuous smoking abstinence [ Time Frame: 26 weeks ]Self-reported continuous smoking abstinence: a self-report of smoking ≤ 5 cigarettes from the past 1, 2, 3, 4, 8, 12, 16, 20 and 26 weeks.
- Reductions in number of cigarettes smoked per day [ Time Frame: 26 weeks ]Reductions in number of cigarettes smoked per day: will be assessed by comparing the number of cigarettes smoked per day at baseline and at 26 weeks. Cigarettes smoked per day: number of cigarettes smoked per day within seven days or the approximate total number of smoked cigarettes within seven days if not smoked daily.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 25 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Cigarette smokers (smoked more than 100 cigarettes in their lifetime, and currently smoke five or more cigarettes a day)
- 25 years of age or older
- Being able to read and write in Chinese
- Owning a smartphone
- Have experience of using apps
- Expressing an interest in quitting smoking within the next month
- Willing to provide informed consent to participate in the study
Exclusion Criteria:
- Nonsmokers
- Only use electronic cigarettes
- Smokers without attempts to quit smoking
- Participants with severe mental illness
- Participants who had already started their quit attempt or using any smoking cessation treatment at the time of registration
- Unable to use smartphone and apps
- Unable to read and write in Chinese

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04421170
Contact: Yanhui Liao, MD | 8615116225099 | tangliaoyanhui@163.com |
China, Zhejiang | |
Yanhui Liao | Recruiting |
Hangzhou, Zhejiang, China, 310016 | |
Contact: Yanhui Liao, MD 8615116225099 liaoyanhui@zju.edu.cn |
Principal Investigator: | Yanhui Liao, MD | Department of Psychiatry, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University |
Responsible Party: | Yanhui Liao, Principal Investigator, Sir Run Run Shaw Hospital |
ClinicalTrials.gov Identifier: | NCT04421170 |
Other Study ID Numbers: |
20200129-33 |
First Posted: | June 9, 2020 Key Record Dates |
Last Update Posted: | January 24, 2022 |
Last Verified: | January 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | All collected IPD, all IPD that underlie results in a publication. |
Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) Informed Consent Form (ICF) Clinical Study Report (CSR) Analytic Code |
Time Frame: | Starting 1 month after publication. |
Access Criteria: | Yanhui Liao will review requests and criteria for reviewing requests |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |